• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » “Electronic nose” detects cancer

“Electronic nose” detects cancer

April 21, 2011
CenterWatch Staff

The development of breath tests that could detect head-and-neck cancer have made some advancement, according to Pharma Times.

Researchers from the Technion-Israel Institute of Technology conducted a small study in  which they took breath samples from 82 people from three groups: head-and-neck cancer patients, lung cancer patients and healthy people. The team then examined the differences in the molecules present in the exhaled breath of each group using “tailor-made detection equipment” called the Nano Artificial NOSE (NA-NOSE).

The researchers found the NA-NOSE was able to distinguish between molecules found in the exhaled breath of head-and-neck cancer patients and healthy volunteers as well as between lung cancer patients and healthy controls.  Additionally, the NA-NOSE was able to detect differences between the two cancer groups.

Researcher Hossam Haick said there is “an urgent need to develop new ways to detect head-and-neck cancer because diagnosis of the disease is complicated, requiring specialist examinations.”  Diagnosis is often late, because symptoms are not specific; yet, patients often develop a second primary tumor that can affect the entire respiratory system.

Lesley Walker, Cancer Research U.K.’s director of cancer information, said “these interesting initial results show promise” but noted that “it’s important to be clear that this is a small study, at a very early stage.”

The study has been published in the British Journal of Cancer. 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing